EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Proposal received to offer $115-$125m in cash for POC business.

EKF Diagnostics Holdings plc announced on 2 April 2015 that the Board of Directors had initiated a strategic review headed by a Committee of the Non-Executive Directors of EKF.

EKF Diagnostics Holdings plc announces conclusion of Strategic Review. 

EKF Diagnostics Holdings plc provides the following trading update for the six months ending 30 June 2015.

EKF Diagnostics, the global in vitro diagnostics company, announces the international launch of the Altair™ 240 clinical chemistry analyzer at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo in Atlanta, Ga, 26-30 July.

EKF Diagnostics, the global in vitro diagnostics company, announces the appointment of a number of senior personnel to key new roles to drive new product introductions.

EKF Diagnostics will be exhibiting its range of molecular diagnostics products supporting personalized medicine in cancer at the 2015 American Society of Clinical Oncology (ASCO) annual meeting, 29th May to 2nd June, McCormick Place, Chicago, Illinois.

EKF Diagnostics will be highlighting its expanding Stanbio clinical chemistry range at Hospitalar, 19-­22 May in Sao Paulo, Brazil. 

EKF Diagnostics announces the launch of its next generation sequencing technology PrecisionPath™ in partnership with Greenville Health Systems, one of the leading cancer institutes in the US.